Literature DB >> 16283378

Immunohistochemical expression of p63, p53 and MIB-1 in urinary bladder carcinoma. A tissue microarray study of 158 cases.

Eva Compérat1, Philippe Camparo, Rachel Haus, Emmanuel Chartier-Kastler, Stephane Bart, Annick Delcourt, Alain Houlgatte, Richard François, Fréderique Capron, Annick Vieillefond.   

Abstract

P63 is a member of the p53 family, which plays a role in the differentiation of urothelium and is supposed to play a role in urothelial carcinogenesis. P53 and MIB-1 are recognised in many studies as predictive markers of progression, but few studies in the literature have examined p63. The aims of our study were to explore the expression of p63 in bladder carcinomas and to compare this expression to p53 and MIB-1, as well as to stage and grade. Tissue microarrays were performed on 158 urothelial carcinomas (56 pTa, 45 pT1 and 57>or=pT2). Immunohistochemical studies were performed with p63, p53 and MIB-1 antibodies. In our study we observed that p63 immunostaining is present in all cell layers in papillary urothelial neoplasm of low malignant potential (PUNLMP), but partially lost in non-invasive papillary urothelial carcinoma low grade (NILGC) and in pT1/>or=pT2 bladder cancers. P53 and MIB-1 displayed lower expression in PUNLMP/NILGC vs non-invasive papillary urothelial carcinoma high grade (NIHGC)/pT1, but there was no correlation between the expression of p63, p53 and MIB-1. Our study demonstrates that p63 expression distinguishes between PUNLMP/NILGC and NIHGC/pT1 (p=4.10(5)). A statistical difference disserving pTa and pT1/>or=pT2 with a statistical significance (p<10(-6)) could also be observed. P63 should be considered as an additional biomarker that might help pathologists to classify their patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16283378     DOI: 10.1007/s00428-005-0092-2

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  48 in total

1.  Positive and negative regulation of deltaN-p63 promoter activity by p53 and deltaN-p63-alpha contributes to differential regulation of p53 target genes.

Authors:  David Christopher Harmes; Edward Bresnick; Emma A Lubin; Julie K Watson; Kelly E Heim; Joshua C Curtin; Anne M Suskind; Justin Lamb; James DiRenzo
Journal:  Oncogene       Date:  2003-10-23       Impact factor: 9.867

2.  The relationship between p63 and p53 expression in normal and neoplastic breast tissue.

Authors:  Alfredo Ribeiro-Silva; Leandra N Zambelli Ramalho; Sérgio Britto Garcia; Sérgio Zucoloto
Journal:  Arch Pathol Lab Med       Date:  2003-03       Impact factor: 5.534

3.  Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification.

Authors:  Lúcio Santos; Teresina Amaro; Céu Costa; Sofia Pereira; Maria José Bento; Paula Lopes; Jorge Oliveira; Begoña Criado; Carlos Lopes
Journal:  Int J Cancer       Date:  2003-06-10       Impact factor: 7.396

Review 4.  p63.

Authors:  Natalie A Little; Aart G Jochemsen
Journal:  Int J Biochem Cell Biol       Date:  2002-01       Impact factor: 5.085

5.  Frequent alteration of p63 expression in human primary bladder carcinomas.

Authors:  B J Park; S J Lee; J I Kim; S J Lee; C H Lee; S G Chang; J H Park; S G Chi
Journal:  Cancer Res       Date:  2000-07-01       Impact factor: 12.701

6.  Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers.

Authors:  K Hagiwara; M G McMenamin; K Miura; C C Harris
Journal:  Cancer Res       Date:  1999-09-01       Impact factor: 12.701

7.  TAp63gamma (p51A) and dNp63alpha (p73L), two major isoforms of the p63 gene, exert opposite effects on the vascular endothelial growth factor (VEGF) gene expression.

Authors:  Makoto Senoo; Yasuko Matsumura; Sonoko Habu
Journal:  Oncogene       Date:  2002-04-11       Impact factor: 9.867

8.  Immunohistochemical evaluation of p53 oncoprotein in transitional cell carcinoma of the upper urinary tract.

Authors:  K Nakanishi; T Kawai; C Torikata
Journal:  Hum Pathol       Date:  1996-12       Impact factor: 3.466

9.  P63 immunoreactivity distinguishes upper urinary tract transitional-cell carcinoma and renal-cell carcinoma even in poorly differentiated tumors.

Authors:  Cord Langner; Manfred Ratschek; Oleksiy Tsybrovskyy; Luigi Schips; Richard Zigeuner
Journal:  J Histochem Cytochem       Date:  2003-08       Impact factor: 2.479

Review 10.  Prognostic markers in muscle invasive bladder cancer.

Authors:  Rabi Tiguert; Annie Lessard; Alan So; Yves Fradet
Journal:  World J Urol       Date:  2002-06-07       Impact factor: 4.226

View more
  17 in total

1.  Ki67 and TP53 expressions predict recurrence of non-muscle-invasive bladder cancer.

Authors:  Lujia Wang; Chenchen Feng; Guanxiong Ding; Qiang Ding; Zhongwen Zhou; Haowen Jiang; Zhong Wu
Journal:  Tumour Biol       Date:  2013-11-17

Review 2.  Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer.

Authors:  David J McConkey; Woonyoung Choi; Lauren Marquis; Frances Martin; Michael B Williams; Jay Shah; Robert Svatek; Aditi Das; Liana Adam; Ashish Kamat; Arlene Siefker-Radtke; Colin Dinney
Journal:  Cancer Metastasis Rev       Date:  2009-12       Impact factor: 9.264

3.  Ki-67 and Cell Cycle Regulators p53, p63 and cyclinD1 as Prognostic Markers for Recurrence/ Progression of Bladder Urothelial Carcinoma.

Authors:  Saba El-Gendi; Ghada Abu-Sheasha
Journal:  Pathol Oncol Res       Date:  2017-05-09       Impact factor: 3.201

4.  Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression.

Authors:  Orit Karni-Schmidt; Mireia Castillo-Martin; Tian Huai Shen; Tian HuaiShen; Nataliya Gladoun; Josep Domingo-Domenech; Marta Sanchez-Carbayo; Yingchun Li; Scott Lowe; Carol Prives; Carlos Cordon-Cardo
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

5.  Spindle cell carcinoma progressed from transitional cell carcinoma of the urinary bladder.

Authors:  Tadashi Terada
Journal:  Int J Clin Exp Pathol       Date:  2012-01-01

Review 6.  Biomarkers for bladder cancer management: present and future.

Authors:  Fei Ye; Li Wang; Mireia Castillo-Martin; Russell McBride; Matthew D Galsky; Jun Zhu; Paolo Boffetta; David Y Zhang; Carlos Cordon-Cardo
Journal:  Am J Clin Exp Urol       Date:  2014-04-05

Review 7.  p63 steps into the limelight: crucial roles in the suppression of tumorigenesis and metastasis.

Authors:  Xiaohua Su; Deepavali Chakravarti; Elsa R Flores
Journal:  Nat Rev Cancer       Date:  2013-02       Impact factor: 60.716

8.  HOXB13 is a sensitive and specific marker of prostate cells, useful in distinguishing between carcinomas of prostatic and urothelial origin.

Authors:  Justine Varinot; Olivier Cussenot; Morgan Roupret; Pierre Conort; Marc-Olivier Bitker; Emmanuel Chartier-Kastler; Liang Cheng; Eva Compérat
Journal:  Virchows Arch       Date:  2013-10-22       Impact factor: 4.064

9.  Sarcomatoid carcinoma of the urinary bladder: a case report with immunohistochemical and molecular genetic analysis.

Authors:  Tadashi Terada
Journal:  Med Oncol       Date:  2009-06-12       Impact factor: 3.064

10.  Caspase-1 is a novel target of p63 in tumor suppression.

Authors:  I Celardo; F Grespi; A Antonov; F Bernassola; A V Garabadgiu; G Melino; I Amelio
Journal:  Cell Death Dis       Date:  2013-05-23       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.